Opus Genetics announced an agreement to license its third preclinical program focused on an inherited retinal disease from Massachusetts Eye and Ear, Harvard Medical School’s ophthalmic teaching hospital, according to a press release.
The OPGx-003 program is a gene augmentation therapy designed to prevent functional degeneration in the retina of pediatric patients with NMNAT1 mutations, which cause a type of Leber congenital amaurosis, and is based on the expertise of Eric Pierce, MD, PhD, director of the Ocular Genomics Institute, professor at Massachusetts Eye and Ear and Harvard